Treatment of Gastroesophageal Reflux Disease (GERD)

1. Lifestyle Modifications

2. Pharmacological Treatment

Step-Up vs. Step-Down Approach

A. Antacids and Alginates

• Antacids neutralize intragastric acid without suppressing subsequent secretion - they provide rapid but short-lived relief.
• The concept of the acid pocket (a layer of newly secreted acid on top of the ingested meal, appearing within 20 minutes of eating) has revived interest in alginate-antacid combinations.
• Alginates (e.g., Gaviscon): natural polysaccharide polymers that precipitate into a viscous gel on contact with gastric acid. The sodium bicarbonate within the formulation releases CO2 which floats the gel on top of gastric contents, displacing the acid pocket and reducing postprandial reflux. - Yamada's Gastroenterology, 7e
• Hyaluronic acid-chondroitin sulfate (Esoxx): forms a protective barrier on the esophageal mucosa. When combined with acid suppression, 53% of NERD patients had symptom relief vs. 32% with acid suppression alone (p < 0.01).

B. Histamine-2 Receptor Antagonists (H2RAs)

• Competitively block histamine-stimulated H2 receptors on parietal cells
• Less potent than PPIs; duration of action parallels serum half-life
• Tachyphylaxis develops rapidly with continuous use
• PPIs are superior to H2RAs for healing erosive esophagitis
• H2RAs remain useful for nocturnal acid breakthrough on PPI therapy (added at bedtime)
• Agents: ranitidine (withdrawn in many countries due to NDMA), famotidine, cimetidine, nizatidine

C. Proton Pump Inhibitors (PPIs) - First-Line Therapy

• Take 30-60 minutes before a meal (to allow absorption and activation during the active secretory phase)
• Standard course: 4-8 weeks for initial healing; maintenance therapy for moderate-severe/erosive disease
• For Barrett's esophagus: once-daily PPI maintenance recommended by ACG guidelines for chemoprevention (reduces risk of high-grade dysplasia/adenocarcinoma; adjusted OR 0.29) - Sleisenger & Fordtran's GI and Liver Disease

• Hypomagnesemia
• Increased risk of Clostridioides difficile infection
• Possible reduction in clopidogrel efficacy (CYP2C19 interaction, mainly omeprazole/esomeprazole)
• Vitamin B12 and iron malabsorption (with prolonged use)
• Bone density reduction (long-term high-dose)
• Community-acquired pneumonia (modest increased risk)

D. Prokinetics

• Augment esophageal peristalsis and improve gastric emptying, reducing reflux volume
• Metoclopramide: dopamine antagonist - limited long-term use due to tardive dyskinesia risk
• Domperidone: less CNS penetration than metoclopramide; used in some countries
• Baclofen: GABA-B agonist that reduces transient LES relaxations (TLESRs) - used in refractory GERD and as add-on to PPIs for persistent regurgitation
• Prokinetics are generally adjuncts, not monotherapy

E. Reflux Inhibitors

• Baclofen (GABA-B agonist): reduces TLESR frequency - the dominant mechanism of reflux in most patients. Used in refractory regurgitation when PPI response is incomplete. Dose-limited by CNS side effects (dizziness, somnolence).

3. Treatment Algorithm

Figure 43.7 - Yamada's Textbook of Gastroenterology, 7e

• Adjust to lowest effective dose
• Consider on-demand therapy if symptoms are mild-moderate
• Consider antireflux surgery if PPI-intolerant

• Tolerate: lifestyle adjustment, weight loss
• Add-on therapy: baclofen (reflux inhibition), address visceral hypersensitivity
• Persistent regurgitation: consider antireflux surgery

• Reconsider diagnosis - proven GERD? Change PPI? Surgery?
• If visceral hypersensitivity predominates: low-dose antidepressant, acupuncture, hypnotherapy

4. Surgical Treatment - Antireflux Surgery (ARS)

Indications

• Medically refractory symptoms
• Patient preference (desire to stop long-term PPIs)
• Barrett's esophagus with ongoing symptomatic reflux
• Extraesophageal complications (laryngopharyngeal reflux, aspiration, pulmonary disease) - antireflux surgery improves respiratory symptoms in ~90% of children and ~70% of adults with asthma and GERD
• Medication intolerance/noncompliance
• Young patients averse to lifelong pharmacotherapy
• Fischer's Mastery of Surgery, 8e; Maingot's Abdominal Operations

Procedures

LOTUS Trial Evidence

• Both treatments similarly effective in achieving complete symptom remission at 3 years
• At 5 years: remission rates 92% (esomeprazole) vs. 85% (fundoplication), p=0.048
• Regurgitation was significantly better controlled surgically (13% surgical vs. 2% medical failure, p<0.001)
• Dysphagia, bloating, flatulence: more common in fundoplication group

Contraindications to Surgery

• Absolute: Absent esophageal peristalsis (e.g., scleroderma)
• Relative: Severe esophagitis with stricture, short esophagus, prior upper abdominal surgery, severe peristaltic dysfunction
• Pre-operative esophageal manometry is mandatory to exclude achalasia and assess peristaltic function

Surgical Complications/Risks

• Dysphagia (most common postoperative complaint)
• Gas-bloat syndrome (inability to belch, flatulence)
• Diarrhea, bowel symptoms
• Recurrence: ~30% resume PPI therapy within 5 years in community practice
• Revision surgery needed in up to 50% at referral centers

5. Endoscopic Therapies

• Radiofrequency ablation at the LES (Stretta procedure): Delivers RF energy to the LES to increase muscle bulk/reduce TLESR. Improves heartburn but not acid exposure on pH testing.
• Transoral incisionless fundoplication (TIF/EsophyX): Endoscopic reconstruction of the flap valve. Suitable for small hiatal hernias; inferior to surgical fundoplication for severe GERD.
• LINX device (magnetic sphincter augmentation): A ring of magnetic beads implanted laparoscopically around the GEJ. Opens with swallowing pressure; prevents reflux at rest. Reversible. Contraindicated in MRI-dependent patients (older models) and nickel allergy.

6. Special Populations

Barrett's Esophagus

• Maintain PPI therapy indefinitely (ACG guideline) for chemoprevention
• Fundoplication is not superior to medical therapy for cancer prevention based on meta-analyses (IRR 0.76 for surgery vs. medical, overall effect similar)
• Patients with Barrett's may be rendered asymptomatic by PPIs while still having pathological acid exposure - pH monitoring may be needed to confirm adequate control
• Sleisenger & Fordtran's GI and Liver Disease

Pediatric GERD

• Infants: formula thickening, volume reduction, positional adjustments first
• Pharmacological acid suppression as next step
• Fundoplication reserved for life-threatening complications (apnea, severe aspiration, failure to thrive refractory to medical therapy)
• Age-appropriate dosing; H2RAs and PPIs both used
• Sabiston Textbook of Surgery, 21e

GERD in Athletes

• Particularly worsens with endurance and high-intensity exercise (exercise-induced LES relaxation)
• Avoid aggravating foods, solid food 3 hours before exercise, adequate hydration
• PPIs are effective and do not affect performance
• Textbook of Family Medicine, 9e

Summary Table